{"id":"https://openalex.org/W2007198928","doi":"https://doi.org/10.1002/cncr.24033","title":"Cost\u2010effectiveness analysis of lapatinib in HER\u20102\u2013positive advanced breast cancer","display_name":"Cost\u2010effectiveness analysis of lapatinib in HER\u20102\u2013positive advanced breast cancer","publication_year":2009,"publication_date":"2009-01-02","ids":{"openalex":"https://openalex.org/W2007198928","doi":"https://doi.org/10.1002/cncr.24033","mag":"2007198928","pmid":"https://pubmed.ncbi.nlm.nih.gov/19117341"},"language":"en","primary_location":{"id":"doi:10.1002/cncr.24033","doi":"https://doi.org/10.1002/cncr.24033","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.24033","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.24033","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.24033","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033092324","display_name":"Quang A. Le","orcid":"https://orcid.org/0000-0002-4968-9334","observed_orcids":["https://orcid.org/0000-0002-4968-9334","https://orcid.org/0000-0002-8828-9392"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Quang A. Le","raw_affiliation_strings":["Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California 90089-9004, USA. quangle@usc.edu","Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California 90089-9004, USA. quangle@usc.edu","institution_ids":["https://openalex.org/I1174212"]},{"raw_affiliation_string":"Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California","institution_ids":["https://openalex.org/I1174212"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080378534","display_name":"Joel W. Hay","orcid":"https://orcid.org/0000-0002-4467-9997","observed_orcids":["https://orcid.org/0000-0002-4467-9997"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joel W. Hay","raw_affiliation_strings":["Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California","institution_ids":["https://openalex.org/I1174212"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5033092324"],"corresponding_institution_ids":["https://openalex.org/I1174212"],"apc_list":{"value":4790,"currency":"USD","value_usd":4790},"apc_paid":null,"fwci":17.1598,"has_fulltext":true,"cited_by_count":57,"citation_normalized_percentile":{"value":0.98879619,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"115","issue":"3","first_page":"489","last_page":"498"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":1.0},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9120000004768372},{"id":"https://openalex.org/keywords/advanced-breast-cancer","display_name":"advanced breast cancer","score":0.9660000205039978},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9829999804496765},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8460000157356262},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8410000205039978},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.9819999933242798},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8379999995231628},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.6480000019073486},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.4560000002384186}],"concepts":[{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.9500526785850525},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9064063429832458},{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.7923963069915771},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6100517511367798},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5670309662818909},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.5564033389091492},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5305664539337158},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5255752205848694},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47324830293655396},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.43523871898651123},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.43231895565986633},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4240078330039978},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.20153823494911194},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077341","descriptor_name":"Lapatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D012680","descriptor_name":"Sensitivity and Specificity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018734","descriptor_name":"Genes, erbB-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/cncr.24033","doi":"https://doi.org/10.1002/cncr.24033","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.24033","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.24033","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},{"id":"pmid:19117341","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19117341","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1002/cncr.24033","doi":"https://doi.org/10.1002/cncr.24033","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.24033","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.24033","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2007198928.pdf","grobid_xml":"https://content.openalex.org/works/W2007198928.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W1512398135","https://openalex.org/W1562415841","https://openalex.org/W1580691413","https://openalex.org/W1861968676","https://openalex.org/W1980131460","https://openalex.org/W1989456077","https://openalex.org/W2011000634","https://openalex.org/W2011659383","https://openalex.org/W2013754529","https://openalex.org/W2020460752","https://openalex.org/W2038863791","https://openalex.org/W2056060263","https://openalex.org/W2059170159","https://openalex.org/W2066346982","https://openalex.org/W2095950656","https://openalex.org/W2110444464","https://openalex.org/W2139994556","https://openalex.org/W2141393790","https://openalex.org/W2167766783","https://openalex.org/W2231156824","https://openalex.org/W2243277621","https://openalex.org/W2477954033","https://openalex.org/W2521733332","https://openalex.org/W2749990448","https://openalex.org/W2960184527"],"related_works":["https://openalex.org/W2589834246","https://openalex.org/W1991856603","https://openalex.org/W2142284502","https://openalex.org/W4293029338","https://openalex.org/W4385697913","https://openalex.org/W2049958999","https://openalex.org/W2267431955","https://openalex.org/W2058769252","https://openalex.org/W4302009608","https://openalex.org/W4309066571"],"abstract_inverted_index":{"BACKGROUND:":[0],"A":[1,48,209],"recent":[2],"clinical":[3,68,84,114],"trial":[4],"demonstrated":[5],"that":[6,218],"the":[7,14,31,37,43,66,83,107,110,126,160,202,219,236,257],"addition":[8,161,237],"of":[9,16,30,39,72,86,116,125,135,162,180,192,201,238],"lapatinib":[10,163,239],"to":[11,26,35,64,81,164,171,207,240,249],"capecitabine":[12,165,241],"in":[13,152,233,251],"treatment":[15],"HER-2-positive":[17],"advanced":[18],"breast":[19],"cancer":[20],"(ABC)":[21],"significantly":[22],"increases":[23],"median":[24],"time":[25],"progression.":[27],"The":[28,75,143,197],"objective":[29],"current":[32],"analysis":[33],"was":[34,62,169],"assess":[36],"cost-effectiveness":[38,189,210],"this":[40,73],"therapy":[41,168],"from":[42,109,140,205],"US":[44,154],"societal":[45,258],"perspective.":[46],"METHODS:":[47],"Markov":[49],"model":[50,76,144],"comprising":[51],"4":[52],"health":[53],"states":[54],"(stable":[55],"disease,":[56],"respond-to-therapy,":[57],"disease":[58,136],"progression,":[59],"and":[60,69,92,97,112,122,133,150,246],"death)":[61],"developed":[63],"estimate":[65],"projected-lifetime":[67],"economic":[70],"implications":[71],"therapy.":[74],"used":[77,145],"Monte":[78],"Carlo":[79],"simulation":[80],"imitate":[82],"course":[85],"a":[87,146,158],"typical":[88],"patient":[89],"with":[90,94,176,228],"ABC":[91],"updated":[93],"response":[95],"rates":[96],"major":[98,128],"adverse":[99,129],"effects.":[100],"Transition":[101],"probabilities":[102],"were":[103,138],"estimated":[104,170],"based":[105],"on":[106],"results":[108],"EGF100151":[111],"EGF20002":[113],"trials":[115],"lapatinib.":[117],"Health":[118],"state":[119],"utilities,":[120],"direct":[121],"indirect":[123],"costs":[124,134],"therapy,":[127],"events,":[130],"laboratory":[131],"tests,":[132],"progression":[137],"obtained":[139],"published":[141],"sources.":[142],"3%":[147],"discount":[148],"rate":[149],"reported":[151],"2007":[153],"dollars.":[155],"RESULTS:":[156],"Over":[157],"lifetime,":[159],"as":[166],"combination":[167],"cost":[172],"an":[173,177,187,252],"additional":[174],"$19,630,":[175],"expected":[178],"gain":[179],"0.12":[181],"quality-adjusted":[182],"life":[183],"years":[184],"(QALY)":[185],"or":[186],"incremental":[188],"ratio":[190],"(ICER)":[191],"$166,113":[193],"per":[194],"QALY":[195],"gained.":[196],"95%":[198],"confidence":[199],"limits":[200],"ICER":[203,220,253],"ranged":[204],"$158,000":[206],"$215,000/QALY.":[208],"acceptability":[211],"curve":[212],"indicated":[213],"less":[214],"than":[215,224,256],"1%":[216],"probability":[217],"would":[221],"be":[222],"lower":[223],"$100,000/QALY.":[225],"CONCLUSIONS:":[226],"Compared":[227],"commonly":[229],"accepted":[230],"willingness-to-pay":[231,259],"thresholds":[232],"oncology":[234],"treatment,":[235],"is":[242],"not":[243],"clearly":[244],"cost-effective;":[245],"most":[247],"likely":[248],"result":[250],"somewhat":[254],"higher":[255],"threshold":[260],"limits.":[261]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":10}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}